Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Liabilities from Discontinued Operations (2017)

Harvard Bioscience (HBIO) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 1857000.0 as the latest value for Q4 2017.

  • On a quarterly basis, Liabilities from Discontinued Operations changed N/A to 1857000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 1857000.0, a N/A change, with the full-year FY2017 number at 1857000.0, changed N/A from a year prior.
  • Liabilities from Discontinued Operations was 1857000.0 for Q4 2017 at Harvard Bioscience.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 1857000.0 in Q4 2017 to a low of 1857000.0 in Q4 2017.